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EndocannabinoidMammalian diacylglycerol kinases are a family of enzymes that catalyze the phosphorylation of diacylglycerol
to produce phosphatidic acid. The extent of interaction of these enzymes with monoacylglycerols is the focus
of the present study. Because of the structural relationship between mono- and diacylglycerols, one might
expect the monoacylglycerols to be either substrates or inhibitors of diacylglycerol kinases. This would have
some consequence to lipid metabolism. One of the lipid metabolites that would be affected is 2-arachidonoyl
glycerol, which is an endogenous ligand for the CB1 cannabinoid receptor. We determined if the
monoglycerides 2-arachidonoyl glycerol or 2-oleoyl glycerol affected diacylglycerol kinase activity. We
found that 2-arachidonoyl glycerol is a very poor substrate for either the epsilon or the zeta isoforms of
diacylglycerol kinases. Moreover, 2-arachidonoyl glycerol is an inhibitor for both of these diacylglycerol
kinase isoforms. 2-oleoyl glycerol is also a poor substrate for these two isoforms of diacylglycerol kinases. As
an inhibitor, 2-oleoyl glycerol inhibits diacylglycerol kinase ε less than does 2-arachidonoyl glycerol, while for
diacylglycerol kinase ζ, these two monoglycerides have similar inhibitory potency. These results have
implications for the known role of diacylglycerol kinase ε in neuronal function and in epilepsy since the action
of this enzyme will remove 1-stearoyl-2-arachidonoylglycerol, the precursor of the endocannabinoid
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Diacylglycerol kinase (DGK) from different species exhibits
different speciﬁcities. Thus, bacterial forms of DGK can phosphorylate
ceramide as well as diacylglycerol (DAG), while DGK from yeast
utilizes CTP, rather than ATP, as the source of phosphate [1].
Mammalian DGKs are a family of enzymes comprised of at least 10
isoforms [2]. We undertook this study to evaluate the interactions of
2-acyl-glycerols with isoforms of DGK in order to assess the possible
role of this enzyme family in affecting the concentration of these
signaling lipids in cells as well as to further understand the nature of
substrate and lipid interactions with binding sites on DGKs.
Mammalian isoforms of DGK have only been shown to catalyze the
phosphorylation of one class of lipid substrates, DAG, using only ATP
as the source of phosphate. In the present study, we determined ifstructurally related monoacylglycerols are either substrates or
inhibitors of mammalian DGKs.
A particularly important acyl chain for monoacyl- and diacylgly-
cerols is arachidonic acid. DAG having arachidonic acid at the sn-2
position is an intermediate in phosphatidylinositol cycling. Arachido-
noyl-DAG is preferentially phosphorylated by the isoform DGKε [2].
The monoglyceride with arachidonic acid at the sn-2 position is
2-arachidonoyl glycerol (2-AG). This monoglyceride is an important
ligand for the CB1 cannabinoid receptor [3]. 2-AG is known to be
generated in the brain by the enzyme diacylglycerol (DAG) lipase [4]
and is one of the most abundant molecular species of monoacylgly-
cerols in the brain [5]. The concentration of DAG in brain synapto-
somes is at least an order of magnitude higher than that of 2-AG [6].
Interestingly, even in organisms lacking known cannabinoid recep-
tors, such as nematodes, 2-AG has been identiﬁed [7]. This suggests
that 2-AG, in addition to being a cannabinoid receptor ligand, is also
an intermediate in lipid metabolism in organisms without developed
endocannabinoid systems. The expression of DAG lipase, that
converts DAG to a monoglyceride, is required for axonal growth
during development and for retrograde synaptic signaling at mature
synapses. Endocannabinoid signaling is a key regulator of synaptic
communication throughout the central nervous system [8]. The
lysolipid 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic
acid-containing lysophosphatidic acid is found in rat brain and can
0.5 1.0 1.5 2.0
-40
-20
0
20
40
60
7.6 mol% 2-AG as inhibitor
7.6 mol% 2-OG as inhibitor
[SAG] (mol%)
%
 In
hi
bi
tio
n
Fig. 1. Inhibition of DGKε by 2-AG and 2-OG. Lipid ﬁlms were created with 0.37, 0.57,
0.76, 1.14 and 1.52 mol% SAG as substrate and 7.6 mol% 2-AG or 2-OG as inhibitor and
used in a mixed micelle activity assay. The data are presented as percent inhibition
calculated by taking the ratio of the difference in activity due to inhibition over the
activity without the inhibitor. The data points are mean±SEM, n=3.
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Fig. 2. Effect of varying concentration of 2-AG on inhibition of DGKε. Lipid ﬁlms were
created with 0.76, 1.14, 1.52 and 1.90 mol% SAG as substrate and 0, 5.1, 7.6 and 15.2 mol
% 2-AG as inhibitor and used in a mixed micelle activity assay. The data are presented as
percent relative activity taking the activity of 1.9 mol% SAG with 0 mol% 2-AG as 100%.
The data points are mean±SEM, n=3.
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not known. A principle metabolic fate of this lipid is its hydrolysis by
monoacylglycerol lipase. However, an additional possibility is that
2-AG is also a substrate for diacylglycerol kinase (DGK) to reform
lysophosphatidic acid that is also a signaling lipid [9–12]. This
possibility was tested in the present study.
2. Materials and methods
2.1. Materials
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL) and
were dissolved in 2:1 CHCl3/CH3OH or in pure CHCl3. 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) was stored in 2:1 CHCl3/CH3OH
and 0.1% (wt./vol.) butylated hydroxytoluene (BHT). 2-AG and 2-OG
were stored in C2H5OH. [γ-
32
P]ATP (50 μCi/mL) was purchased from
Perkin Elmer Life Sciences. All other chemicals and reagents were
purchased from Sigma or BioShop Canada.
2.2. Enzyme preparation for DGK enzymatic activity assay
Human DGKε with a C-terminal hexahistidine tag fusion or DGKζ
with a C-terminal FLAG epitope tag fusion were overexpressed in
baculovirus-infected Sf21 cells. The cell pellets were resuspended in
cold lysis buffer (20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 2.4 mM sodium pyrophosphate, 1 mM β-glycerophosphate,
1 mM sodium orthovanadate and 1:1000 dilution of protease
inhibitor (Sigma)) and detergent 1% (vol./vol.) Nonidet P-40 and
kept on ice for 10 min to lyse. The lysates were centrifuged at
100,000g for 30 min at 4 °C to solubilize DGK and the supernatant was
utilized in the mixed micelle activity assays.
2.3. Detergent-phospholipid-mixed micelle-based DGK enzymatic
activity assay
Inhibition of DGKε and DGKζ by 2-AG or 2-OG was studied using
enzymatic activity assays following a previously established protocol
[13–15]. Lipid ﬁlms were prepared by evaporation of organic solvent
of lipid solutions of the substrate 1-stearoyl-2-arachidonoyl glycerol
(SAG) for DGKε or 1,2-dioleoyl glycerol (DOG) for DGKζ. In addition to
the substrate, the phospholipid DOPC was added for DGKε or 1,2-
dioleoyl-sn-glycero-3-[phospho-L-serine] (DOPS) for DGKζ. The
monoglycerides, 2-AG and 2-OG, were tested alone as substrates or
tested as inhibitors with SAG or DOG as substrates. When 2-AG and 2-
OG were tested as substrates, SAG and DOG were not included in the
lipid ﬁlms. DOPC or DOPS were added in addition to other lipids so as
to maintain the total concentration of all lipids at 24.1 mol% (19 mM).The lipids were dried under stream of nitrogen gas to remove the
organic solvent and then further dried in a vacuum dessicator for 2 h.
All lipids and lipid ﬁlms were covered with Argon gas to avoid
oxidation by air. The ﬁlmswere hydratedwith 50 μL of 4× assay buffer
(200 mMTris–HCl (pH 7.5), 400 mMNaCl, 20 mMMgCl2, 4 mMEGTA,
30 mM Triton X-100 and 30 mM Triton X-114) and vortexed for
2 min, followed by addition of 105 μL ddH2O, 20 μL of 10 mM DTT and
5 μL of Sf21 insect cell lysates expressing either DGKε or DGKζ or
empty vector controls, to obtain a ﬁnal volume of 180 μL. The reaction
was initiated with 20 μL of 1 mM [γ-
32
P]ATP (50 μCi/mL) and was
stopped after 10 min at 25 °C with the addition of 2 mL of stop
solution (1:1 CHCl3/CH3OH and 0.25 mg/mL dihexadecyl phosphate).
The organic layer was washed three times. To allow for maximal
separation of the organic and aqueous phases, the mixture was
allowed to stand for 2 h, 20 and 5 min, after the ﬁrst, second and third
wash, respectively, with 2 mL of wash solution (7:1 H2O/CH3OH, 1%
HClO4, 0.1% H3PO4) used for each wash. The aqueous layer was
removed after each wash. Four hundred microliters of the organic
layer was collected in a scintillation vial and incorporation of
radioactive phosphate into the organic phase was measured by
Cerenkov counting using a scintillation counter (Beckman Coulter).
The counts were corrected for a blank reaction in which no enzyme
was added. The activity is presented as % relative activity taking the
control with no inhibitor as 100% activity. The assays were performed
in triplicates and the results are presented as the mean±the standard
deviation of themean. Lysates frommock transfected insect cells were
used as negative controls.
3. Results
Because of the speciﬁc binding of DGKε to an arachidonoyl group,
there was a particular interest to evaluate the behavior of 2-AG with
this isoform of DGK. The substrate speciﬁcity and kinetic constants for
DGKε has been recently reported [13]. Using the preferred substrate of
DGKε, SAG, as a positive control, the rate of phosphorylation of 2-AG
was only 6.35%±0.15% that of SAG. Thus, 2-AG essentially is a very
poor substrate for DGKε. We also evaluated 2-OG as a substrate of this
isoform of DGK, but the rate of phosphorylation was even lower than
for 2-AG, reﬂecting the speciﬁcity of DGKε for arachidonoyl-contain-
ing lipids.
A possible contribution to the slow rate of phosphorylation of
these monoglycerides is that their partitioning between aqueous and
micellar phases favors water solubility. However, this is not a major
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Fig. 3. Inhibition of DGKζ by 2-AG and 2-OG. Lipid ﬁlms were created with 0.37, 0.57,
0.76, 1.14 and 1.52 mol% DOG as substrate and 7.6 mol% 2-AG or 2-OG as inhibitor and
used in a mixed micelle activity assay. The data are presented as percent relative
activity taking the activity of 1.52 mol% DOG without any inhibitor as 100%. The data
points are mean±SEM, n=3.
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more water soluble of the two monoglycerides. In addition, in pure
form these monoglycerides are insoluble in water but readily soluble
in organic solvent. Lastly, although they are poor substrates, we show
below that these monoglycerides can inhibit various isoforms of DGK
and can therefore partition into the membrane.
The monoglyceride, 2-AG, was also tested as an inhibitor of DGKε.
About 7.6 mol% 2-AG was added to micelles containing different
amounts of SAG (Fig. 1). The concentration dependence of the
inhibition is complex and could not be analyzed quantitatively with
any simple kinetic model. At low concentration of SAG, there is no
inhibition by 2-AG likely because the 2-AG is a weak substrate. At
higher concentrations of SAG, however, there is signiﬁcant inhibition
by 2-AG. At sufﬁciently high concentrations of 2-AG, there is
essentially complete inhibition of the activity of DGKε in phosphor-
ylating SAG (Fig. 2). The error bars given for this graph represent the
precision of replicates in the assay performed under identical
experimental conditions. There is somewhat greater experiment-to-
experiment variation, likely resulting from factors such as different
cell lysates being used as the source of enzyme for different
experiments as well as the purity of the monoglyceride that is
susceptible to both acyl chain migration as well as oxidation of the
2-AG. The extent of inhibition shown in Fig. 2 is somewhat greater
than that presented in Fig. 1. Nevertheless, it is clear that the
inhibition by 2-AG is much greater than that by 2-OG (Fig. 1). 2-OG
has essentially no activity as either a substrate or as an inhibitor for
the epsilon isoform of DGK.
In contrast with DGKε, the isoform DGKζ exhibits similar
inhibition with 2-OG and 2-AG (Fig. 3). A determination of the
Michaelis–Menten constants of DGKζ has been recently studied in
comparison with other isoforms [16].
4. Discussion
The ﬁnding that neither 2-AG nor 2-OG is a substrate for DGKε or
DGKζ shows the speciﬁcity of DGKs for diacylglycerols. This is the case
even for DGKε that has been shown to have a particularly strong
speciﬁcity for an arachidonoyl group on the substrate [2]. We have
previously shown that DGKε also has speciﬁcity for the acyl chain at
the sn-1 position with 18:0 being the most favorable acyl chain at that
position [13]. The diacylglycerol becomes a poorer substrate as the
acyl chain becomes shorter than 18 carbons, but the effect is modest
for fatty acids. However, when the acyl chain is completely absent, as
with 2-AG, the lipid is essentially no longer a substrate.
We have previously demonstrated that the enantiomer of the
natural stereoisomer 1,2-dioleoylglycerol, i.e., 2,3-dioleoylglycerol,exhibits greater inhibition of DGKζ than of DGKε [16]. Similarly, we
have determined that 2-AG and 2-OG have a very low potency of
inhibition against DGKε compared with the inhibition of these
monoglycerides with DGKζ. This behavior is analogous to the relative
inhibitory effects of 2,3-dioleoylglycerol [16]. Since DGKε is more
selective in substrate binding than other mammalian DGK isoforms, it
is less inhibited by either 2,3-dioleoylglycerol or by 2-OG, than other
mammalian DGK isoforms. In addition, although not a potent
inhibitor, 2-AG is a better inhibitor of DGKε than is 2-OG. These
results can be explained by the fact that DGKε binds arachidonoyl-
containing lipids more speciﬁcally, as is also indicated by the
arachidonoyl substrate speciﬁcity of this isoform.
In addition to furthering our understanding of the properties of
diacylglycerol kinases, there may be relevance of these ﬁndings to the
role of endocannabinoids in neuronal function. 2-AG is an endocan-
nabinoid that can arise from the DAG lipase catalyzed cleavage of SAG,
the preferred substrate of DGKε. Another route of metabolism of SAG
is by DGKε-catalyzed phosphorylation to generate SAPA. In DGKε
knockout mice, the conversion of this particular species of diacylgly-
cerol to phosphatidic acid is reduced [17]. Consequently, an
alternative path for the SAG metabolism would be its conversion to
the endocannabinoid, 2-AG by the DAG lipase. Based on our ﬁndings
on the inhibitory property of 2-AG on DGKε, there could be a weak
feed-forward effect of 2-AG on its own formation as a result of its
inhibition of DGKε.
This pathway appears to have importance in epilepsy. DGKε(−/−)
mice had signiﬁcantly fewer motor seizure and epileptic events
compared with DGKε(+/+) mice [18]. This could be explained by the
fact that in the knockout mice a greater fraction of the SAG would be
converted to 2-AG. 2-AG itself is known to have anticonvulsive effects
through activation of cannabinoid receptors [19]. Pharmacological
studies have shown that it is the type 1 cannabinoid receptor that is
linked to epileptic events [20]. The natural resistance of certain
species to epileptic seizures has been suggested to be a consequence
of their high level of expression of type 1 cannabinoid receptors [21].
The formation of 2-AG resulting in the activation of type 1
cannabinoid receptors will be affected by the activity of DGKε that
reduces the fraction of SAG converted to 2-AG. The present study
describes the relationship between 2-AG and DGKs that could
impinge on neuronal function.Acknowledgements
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